ArticleThe European respiratory journal2016
Beryllium-induced lung disease exhibits expression profiles similar to sarcoidosis.
Article in The European respiratory journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Immune regulation by CD55 in chronic beryllium disease.American journal of respiratory cell and molecular biology · 2026Article
- Single cell transcriptome signatures and cell-cell interactions associated with sarcoidosis in lung immune cell populations.Frontiers in immunology · 2026Article
- Overview of multi-omics approaches for pulmonary sarcoidosis.EC pulmonology and respiratory medicine · 2025Article
- Molecularly Targeted Therapies for Inflammatory Cutaneous Granulomatous Disorders: A Review of the Evidence and Implications for Understanding Disease Pathogenesis.JID innovations : skin science from molecules to population health · 2023Review
- Differential diagnosis of pulmonary sarcoidosis: a review.Frontiers in medicine · 2023Review
- Multiomic Signatures of Chronic Beryllium Disease Bronchoalveolar Lavage Cells Relate to T-Cell Function and Innate Immunity.American journal of respiratory cell and molecular biology · 2022Article
- The Role ofMicroorganisms · 2022Review
- Innate and Adaptive Immunity in Noninfectious Granulomatous Lung Disease.Journal of immunology (Baltimore, Md. : 1950) · 2022Review
- Genomic biomarkers in chronic beryllium disease and sarcoidosis.Respiratory medicine · 2021Article
- Proteomic characteristics of beryllium sulfate-induced differentially expressed proteins in rats.Toxicology research · 2021Article
- Single-cell RNA sequencing identifies macrophage transcriptional heterogeneities in granulomatous diseases.The European respiratory journal · 2021Article
- Beryllium-specific CD4+ T cells induced by chemokine neoantigens perpetuate inflammation.The Journal of clinical investigation · 2021Article
- Age-associated B Cells Appear in Patients with Granulomatous Lung Diseases.American journal of respiratory and critical care medicine · 2020Article
- Novel protein pathways in development and progression of pulmonary sarcoidosis.Scientific reports · 2020Article
- Current Sarcoidosis Models and the Importance of Focusing on the Granuloma.Frontiers in immunology · 2020Review
- Polymorphism of FCGR3A gene in chronic beryllium disease.Genes and immunity · 2019Article
- DNA Methylation Changes in Lung Immune Cells Are Associated with Granulomatous Lung Disease.American journal of respiratory cell and molecular biology · 2019Article
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.Nature reviews. Drug discovery · 2017Article
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.Nature reviews. Drug discovery · 2017Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
A subset of beryllium-exposed workers develop beryllium sensitisation (BeS) which precedes chronic beryllium disease (CBD). We conducted an in-depth analysis of differentially expressed candidate genes in CBD.We performed Affymetrix GeneChip 1.0 ST array analysis on peripheral blood mononuclear cells (PBMCs) from 10 CBD, 10 BeS and 10 beryllium-exposed, nondiseased controls stimulated with BeSO4 or medium. The differentially expressed genes were validated by high-throughput real-time PCR in this group and in an additional group of cases and nonexposed controls. The functional roles of the top candidate genes in CBD were assessed using a pharmacological inhibitor. CBD gene expression data were compared with whole blood and lung tissue in sarcoidosis from the Gene Expression Omnibus.We confirmed almost 450 genes that were significantly differentially expressed between CBD and controls. The top enrichment of genes was for JAK (Janus kinase)-STAT (signal transducer and activator of transcription) signalling. A JAK2 inhibitor significantly decreased tumour necrosis factor-α and interferon-γ production. Furthermore, we found 287 differentially expressed genes overlapped in CBD/sarcoidosis. The top shared pathways included cytokine-cytokine receptor interactions, and Toll-like receptor, chemokine and JAK-STAT signalling pathways.We show that PBMCs demonstrate differentially expressed gene profiles relevant to the immunnopathogenesis of CBD. CBD and sarcoidosis share similar differential expression of pathogenic genes and pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.